logo

For the Inventor, By the Inventor

Loerrach, Germany

Hans Allgeier

This inventor holds 24 USPTO granted patents and 2 published patent applications and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Ciba-Geigy Corporation, Novartis Ag, Other. Active years: 1976-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans Allgeier. Retrieved from https://idiyas.com/inventor/hans-allgeier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 24 

% Patents Active = 83.3

 

Average Co-Inventor Count = 2.2

ph-index = 6

Forward Citations = 123(Granted Patents)


Location History:

  • Haagen, BD., DE (1976)
  • Haagen, DE (1976 - 1984)
  • Lorrach-Haagen, DE (1979 - 1994)
  • Lorrach, DE (1996 - 2000)
  • Lörrach, DE (2003)
  • Loerrach, DE (2010 - 2013)

Company Filing History:

goldMedal17 out of 6,858 
 
Ciba-Geigy Corporation
 patents
silverMedal6 out of 3,978 
 
Novartis Ag
 patents
bronzeMedal1 out of 834,659 
Other
 patents

Years Active: 1976-2013

Loading Chart...
Loading Chart...
Areas of Expertise:
Quinazoline Derivatives
Anticonvulsants
Triazole Compounds
Amino Acids
Pharmaceutical Compositions
Dioxo Derivatives
Purines
Carboxamide Compounds
Diazepine Derivatives
Heteroaliphatyl
Phosphonic Acids
Benzodiazepine
24 patents (USPTO):Explore Patents
1. 8513268 - 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy (2013-08-20),
2. 8299085 - Quinazoline derivatives (2012-10-30),
3. 8012988 - N-(2,4-dioxo-6-(tetrahydrofuran-2-yl)-7-(trifluoromethyl)-1,4-dihydro-2H-quinazolin-3-yl)methanesulfonamide (2011-09-06),
4. 7655666 - Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands (2010-02-02),
5. 6656957 - Pyridine derivatives (2003-12-02),
6. 6117873 - Substituted aminoalkane phosphonic acids (2000-09-12),
7. 6080743 - 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives (2000-06-27),
8. 5633379 - 3-heteroaliphatyl- and 3-hetero(aryl)aliphatyl-2(1H)-quinolone (1997-05-27),
9. 5488140 - 4-substituted 2-aminoalk-3-enoic (1996-01-30),
10. 5294734 - 4-substituted 2-aminoalk-3-enoic acids (1994-03-15),
11. 5175344 - Unsaturated amino acids (1992-12-29),
12. 5134134 - Unsaturated aminodicarboxylic acid derivatives (1992-07-28),
13. 5110818 - Anticonvulsive substituted-9-benzyl-9H-purines (1992-05-05),
14. 5098922 - Aralkyl-4H-1,2,4-triazole derivatives (1992-03-24),
15. 5051413 - Unsaturated amino acids (1991-09-24),

Title: The Inventive Journey of Hans Allgeier in the Pharmaceutical Industry

Introduction:

Hans Allgeier, a prolific inventor hailing from Loerrach, Germany, has left a lasting impact on the field of pharmaceuticals with his innovative solutions and patented inventions.

Latest Patents:

1. 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy.

2. Quinazoline derivatives.

Career Highlights:

Having accumulated an impressive total of 24 patents, Hans Allgeier has been at the forefront of pharmaceutical advancements. His patents encompass a wide range of pharmaceutical compositions and treatment methods, showcasing his versatility and deep expertise in the industry.

Collaborations:

During his illustrious career, Hans Allgeier has collaborated with esteemed professionals such as Yves Auberson and Andre Gagneux. His tenure at reputable companies like Ciba-Geigy Corporation and Novartis AG has further strengthened his position as a pioneer in the pharmaceutical sector.

Conclusion:

In conclusion, Hans Allgeier's groundbreaking work in the pharmaceutical field has not only earned him recognition but has also significantly contributed to the advancement of treatment methods and pharmaceutical compositions. His passion for innovation and commitment to excellence continue to inspire generations of inventors in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…